VFS VinFast Auto | $3.51
-1.7% | 6/10/2025 | Reiterated by | Chardan Capital | Analyst J. Mcilree | Buy -> Buy | $5.50 | Medium | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 6/10/2025 |
RNA Avidity Biosciences | $33.62
+2.9% | 6/9/2025 | Target Raised by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $65.00 -> $75.00 | High | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 6/9/2025 |
RGNX REGENXBIO | $9.81
+2.9% | 6/9/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $52.00 | Low | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 6/9/2025 |
QURE uniQure | $16.34
-3.3% | 5/30/2025 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $38.00 | High | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 5/30/2025 |
WBX Wallbox | $0.34
+0.1% | 5/28/2025 | Upgraded by | Chardan Capital | Analyst J. Mcilree | Hold | | High | View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 5/28/2025 |
TSHA Taysha Gene Therapies | $2.61
-6.8% | 5/29/2025 | Target Raised by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $7.00 -> $9.00 | High | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 5/29/2025 |
RCKT Rocket Pharmaceuticals | $3.16
+4.6% | 5/28/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $46.00 -> $17.00 | High | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/28/2025 |
PRTA Prothena | $5.26
+0.2% | 5/27/2025 | Target Lowered by | Chardan Capital | Analyst R. Li | Buy -> Buy | $40.00 -> $18.00 | High | View details for Chardan Capital rating of Prothena (NASDAQ:PRTA) on 5/27/2025 |
DRUG Bright Minds Biosciences | $28.27
+1.4% | 5/21/2025 | Reiterated by | Chardan Capital | Analyst R. Li | Buy -> Buy | $80.00 -> $80.00 | High | View details for Chardan Capital rating of Bright Minds Biosciences (NASDAQ:DRUG) on 5/21/2025 |
CLSK CleanSpark | $10.13
+0.1% | 5/21/2025 | Initiated by | Chardan Capital | Analyst J. Mcilree | Buy -> Buy | $26.00 -> $20.00 | High | View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 5/21/2025 |
Get the Latest News and Ratings for Your Stocks Enter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. |
PRME Prime Medicine | $1.55
-7.2% | 5/19/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $16.00 -> $12.00 | High | View details for Chardan Capital rating of Prime Medicine (NYSE:PRME) on 5/19/2025 |
SLDB Solid Biosciences | $4.83
+4.5% | 5/19/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $16.00 -> $15.00 | Medium | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 5/19/2025 |
IPSC Century Therapeutics | $0.63
+1.3% | 5/16/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $7.00 -> $6.00 | Low | View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 5/16/2025 |
RCKT Rocket Pharmaceuticals | $3.16
+4.6% | 5/16/2025 | Target Raised by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $45.00 -> $46.00 | High | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/16/2025 |
SABS SAB Biotherapeutics | $1.87
+0.5% | 5/15/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $20.00 -> $20.00 | High | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 5/15/2025 |
ADVM Adverum Biotechnologies | $2.79
-6.1% | 5/15/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $33.00 -> $33.00 | High | View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 5/15/2025 |
MGX Metagenomi | $1.57
-6.0% | 5/15/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $13.00 -> $12.00 | High | View details for Chardan Capital rating of Metagenomi (NASDAQ:MGX) on 5/15/2025 |
MGTX MeiraGTx | $6.86
+8.5% | 5/14/2025 | Target Lowered by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $38.00 -> $35.00 | High | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 5/14/2025 |
COYA Coya Therapeutics | $5.63
-4.3% | 5/13/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $14.00 -> $14.00 | High | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 5/13/2025 |
KRRO Korro Bio | $15.85
+6.7% | 5/13/2025 | Reiterated by | Chardan Capital | Analyst K. Nakae | Buy -> Buy | $25.00 -> $25.00 | High | View details for Chardan Capital rating of Korro Bio (NASDAQ:KRRO) on 5/13/2025 |
OBIO Orchestra BioMed | $3.34
| 5/13/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $20.00 -> $20.00 | High | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 5/13/2025 |
LXEO Lexeo Therapeutics | $4.61
+5.3% | 5/13/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $22.00 -> $20.00 | High | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 5/13/2025 |
ARWR Arrowhead Pharmaceuticals | $16.97
+2.4% | 5/13/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $60.00 -> $60.00 | High | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 5/13/2025 |
XENE Xenon Pharmaceuticals | $32.16
+2.3% | 5/13/2025 | Reiterated by | Chardan Capital | Analyst R. Li | Buy -> Buy | $55.00 -> $55.00 | High | View details for Chardan Capital rating of Xenon Pharmaceuticals (NASDAQ:XENE) on 5/13/2025 |
CRVO CervoMed | $7.72
-0.3% | 5/12/2025 | Target Raised by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $14.00 -> $15.00 | Medium | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 5/12/2025 |
QURE uniQure | $16.34
-3.3% | 5/12/2025 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $38.00 -> $38.00 | Low | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 5/12/2025 |
OCGN Ocugen | $1.13
+3.7% | 5/12/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $7.00 -> $7.00 | High | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 5/12/2025 |
FDMT 4D Molecular Therapeutics | $4.47
-6.7% | 5/9/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $28.00 -> $25.00 | Low | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 5/9/2025 |
RCKT Rocket Pharmaceuticals | $3.16
+4.6% | 5/9/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $54.00 -> $45.00 | Low | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 5/9/2025 |
IOVA Iovance Biotherapeutics | $2.38
+7.7% | 5/9/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $30.00 -> $25.00 | N/A | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 5/9/2025 |
OCS Oculis | $19.79
-0.7% | 5/9/2025 | Target Raised by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $28.00 -> $33.00 | High | View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 5/9/2025 |
SLN Silence Therapeutics | $5.15
-3.0% | 5/9/2025 | Target Lowered by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $55.00 -> $35.00 | Low | View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 5/9/2025 |
DYN Dyne Therapeutics | $14.78
+2.6% | 5/9/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $50.00 -> $50.00 | Low | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 5/9/2025 |
PRTA Prothena | $5.26
+0.2% | 5/9/2025 | Reiterated by | Chardan Capital | Analyst R. Li | Buy -> Buy | $40.00 -> $40.00 | Low | View details for Chardan Capital rating of Prothena (NASDAQ:PRTA) on 5/9/2025 |
TNYA Tenaya Therapeutics | $0.69
+0.7% | 5/9/2025 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $9.00 -> $9.00 | High | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 5/9/2025 |
NTLA Intellia Therapeutics | $8.47
+2.3% | 5/9/2025 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $68.00 -> $68.00 | High | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 5/9/2025 |
MNMD Mind Medicine (MindMed) | $7.89
+1.7% | 5/9/2025 | Reiterated by | Chardan Capital | Analyst R. Li | Buy -> Buy | $20.00 -> $20.00 | High | View details for Chardan Capital rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 5/9/2025 |
EYPT EyePoint Pharmaceuticals | $9.21
+3.1% | 5/8/2025 | Target Lowered by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $33.00 -> $27.00 | Low | View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 5/8/2025 |
CGTX Cognition Therapeutics | $0.31
+3.9% | 5/8/2025 | Target Lowered by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $8.00 -> $4.00 | High | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 5/8/2025 |
MCRB Seres Therapeutics | $8.26
+1.3% | 5/8/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Neutral | $1.25 -> $6.00 | High | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 5/8/2025 |
The Robotics Revolution has arrived … and one $7 stock could take off as a result. (Ad) Something big is brewing in Washington.
According to my research, an executive order from President Trump could be just weeks away.
And it holds the potential to trigger one of the most explosive tech booms in US history.
At the center of it all? Robots.
Not the kind that clean your house or pour you coffee.
But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year. This little-known company holds nearly 100 patents and trades for around $7 |
CNTA Centessa Pharmaceuticals | $12.12
+1.5% | 5/8/2025 | Initiated by | Chardan Capital | Analyst Rudy Li | Buy | $30.00 | Low | View details for Chardan Capital rating of Centessa Pharmaceuticals (NASDAQ:CNTA) on 5/8/2025 |
DRUG Bright Minds Biosciences | $28.27
+1.4% | 5/7/2025 | Initiated by | Chardan Capital | Analyst Rudy Li | Buy | $80.00 | Low | View details for Chardan Capital rating of Bright Minds Biosciences (NASDAQ:DRUG) on 5/7/2025 |
PRAX Praxis Precision Medicines | $45.85
+3.0% | 5/7/2025 | Initiated by | Chardan Capital | Analyst Rudy Li | Buy | $80.00 | High | View details for Chardan Capital rating of Praxis Precision Medicines (NASDAQ:PRAX) on 5/7/2025 |
CRSP CRISPR Therapeutics | $42.94
+2.0% | 5/7/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $84.00 -> $82.00 | High | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 5/7/2025 |
XENE Xenon Pharmaceuticals | $32.16
+2.3% | 5/7/2025 | Initiated by | Chardan Capital | Analyst Rudy Li | Buy | $55.00 | Low | View details for Chardan Capital rating of Xenon Pharmaceuticals (NASDAQ:XENE) on 5/7/2025 |
RNA Avidity Biosciences | $33.62
+2.9% | 5/7/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $65.00 -> $65.00 | High | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 5/7/2025 |
KRYS Krystal Biotech | $138.21
+1.6% | 5/7/2025 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $219.00 -> $219.00 | Low | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 5/7/2025 |
IMRX Immuneering | $2.17
| 5/6/2025 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $13.00 -> $13.00 | High | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 5/6/2025 |
QURE uniQure | $16.34
-3.3% | 5/6/2025 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $38.00 -> $38.00 | High | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 5/6/2025 |
IBIO iBio | $0.95
+3.9% | 5/5/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $5.00 -> $5.00 | Medium | View details for Chardan Capital rating of iBio (NYSE:IBIO) on 5/5/2025 |
TRML Tourmaline Bio | $19.00
+0.6% | 5/5/2025 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $70.00 -> $70.00 | Medium | View details for Chardan Capital rating of Tourmaline Bio (NASDAQ:TRML) on 5/5/2025 |
SNTI Senti Biosciences | $3.02
-3.2% | 5/2/2025 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $12.00 -> $12.00 | Low | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 5/2/2025 |
ALNY Alnylam Pharmaceuticals | $302.46
-0.5% | 5/2/2025 | Target Raised by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $300.00 -> $325.00 | Low | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 5/2/2025 |
WBX Wallbox | $0.34
+0.1% | 4/29/2025 | Upgraded by | Chardan Capital | Analyst J. Mcilree | Hold | | High | View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 4/29/2025 |
VFS VinFast Auto | $3.51
-1.7% | 4/29/2025 | Upgraded by | Chardan Capital | Analyst J. Mcilree | Strong-Buy | | Medium | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 4/29/2025 |
CLSK CleanSpark | $10.13
+0.1% | 4/29/2025 | Upgraded by | Chardan Capital | Analyst J. Mcilree | Strong-Buy | | Low | View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 4/29/2025 |
COYA Coya Therapeutics | $5.63
-4.3% | 4/28/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $14.00 -> $14.00 | Low | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 4/28/2025 |
VFS VinFast Auto | $3.51
-1.7% | 4/28/2025 | Reiterated by | Chardan Capital | Analyst K. Nakae | Buy | $13.00 -> $5.50 | Medium | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 4/28/2025 |
UBX Unity Biotechnology | $0.81
+16.0% | 4/23/2025 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $4.00 -> $4.00 | High | View details for Chardan Capital rating of Unity Biotechnology (NASDAQ:UBX) on 4/23/2025 |
TRML Tourmaline Bio | $19.00
+0.6% | 4/23/2025 | Initiated by | Chardan Capital | Analyst Daniil Gataulin | Buy | $70.00 | Low | View details for Chardan Capital rating of Tourmaline Bio (NASDAQ:TRML) on 4/23/2025 |
OBIO Orchestra BioMed | $3.34
| 4/22/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $20.00 -> $20.00 | N/A | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 4/22/2025 |
OCS Oculis | $19.79
-0.7% | 4/17/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $28.00 -> $28.00 | Low | View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 4/17/2025 |
ADVM Adverum Biotechnologies | $2.79
-6.1% | 4/17/2025 | Target Lowered by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $40.00 -> $33.00 | Medium | View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 4/17/2025 |
KRRO Korro Bio | $15.85
+6.7% | 4/16/2025 | Initiated by | Chardan Capital | Analyst Keay Nakae | Buy | $25.00 | Low | View details for Chardan Capital rating of Korro Bio (NASDAQ:KRRO) on 4/16/2025 |
PVLA Palvella Therapeutics | $26.23
-1.5% | 4/9/2025 | Initiated by | Chardan Capital | Analyst Geulah Livshits | Buy | $50.00 | Medium | View details for Chardan Capital rating of Palvella Therapeutics (NASDAQ:PVLA) on 4/9/2025 |
LXEO Lexeo Therapeutics | $4.61
+5.3% | 4/8/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $25.00 -> $22.00 | High | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 4/8/2025 |
OBIO Orchestra BioMed | $3.34
| 4/1/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $20.00 -> $20.00 | High | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 4/1/2025 |
FBRX Forte Biosciences | $12.25
+2.5% | 4/1/2025 | Target Lowered by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $64.00 -> $61.00 | Low | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 4/1/2025 |
SABS SAB Biotherapeutics | $1.87
+0.5% | 4/1/2025 | Target Lowered by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $25.00 -> $20.00 | High | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 4/1/2025 |
QURE uniQure | $16.34
-3.3% | 4/1/2025 | Initiated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $27.00 -> $38.00 | High | View details for Chardan Capital rating of uniQure (NASDAQ:QURE) on 4/1/2025 |
CLSD Clearside Biomedical | $0.81
+6.4% | 3/28/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $6.00 -> $6.00 | High | View details for Chardan Capital rating of Clearside Biomedical (NASDAQ:CLSD) on 3/28/2025 |
ABUS Arbutus Biopharma | $3.55
+1.1% | 3/28/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $5.00 -> $5.00 | High | View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 3/28/2025 |
GANX Gain Therapeutics | $1.89
-1.0% | 3/28/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $6.00 -> $6.00 | High | View details for Chardan Capital rating of Gain Therapeutics (NASDAQ:GANX) on 3/28/2025 |
ALUR Allurion Technologies | $2.73
+0.7% | 3/27/2025 | Reiterated by | Chardan Capital | Analyst K. Nakae | Neutral -> Neutral | $2.50 -> $2.50 | Low | View details for Chardan Capital rating of Allurion Technologies (NYSE:ALUR) on 3/27/2025 |
ZURA Zura Bio | $1.28
+2.4% | 3/26/2025 | Target Lowered by | Chardan Capital | Analyst Matthew Barcus | Buy -> Buy | $12.00 -> $10.00 | High | View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 3/26/2025 |
WBX Wallbox | $0.34
+0.1% | 3/24/2025 | Upgraded by | Chardan Capital | Analyst K. Nakae | Hold | | Low | View details for Chardan Capital rating of Wallbox (NYSE:WBX) on 3/24/2025 |
VFS VinFast Auto | $3.51
-1.7% | 3/24/2025 | Upgraded by | Chardan Capital | Analyst K. Nakae | Strong-Buy | | Low | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 3/24/2025 |
CLSK CleanSpark | $10.13
+0.1% | 3/24/2025 | Upgraded by | Chardan Capital | Analyst K. Nakae | Strong-Buy | | High | View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 3/24/2025 |
LXEO Lexeo Therapeutics | $4.61
+5.3% | 3/25/2025 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $25.00 -> $25.00 | High | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 3/25/2025 |
UBX Unity Biotechnology | $0.81
+16.0% | 3/25/2025 | Target Lowered by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $6.00 -> $4.00 | Low | View details for Chardan Capital rating of Unity Biotechnology (NASDAQ:UBX) on 3/25/2025 |
IMRX Immuneering | $2.17
| 3/24/2025 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $13.00 -> $13.00 | High | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 3/24/2025 |
IPSC Century Therapeutics | $0.63
+1.3% | 3/24/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $11.00 -> $7.00 | Low | View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 3/24/2025 |
ALNY Alnylam Pharmaceuticals | $302.46
-0.5% | 3/21/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $300.00 -> $300.00 | High | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 3/21/2025 |
ALUR Allurion Technologies | $2.73
+0.7% | 3/21/2025 | Reiterated by | Chardan Capital | Analyst K. Nakae | Neutral -> Neutral | $2.50 | High | View details for Chardan Capital rating of Allurion Technologies (NYSE:ALUR) on 3/21/2025 |
CGTX Cognition Therapeutics | $0.31
+3.9% | 3/21/2025 | Target Lowered by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $11.00 -> $8.00 | High | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 3/21/2025 |
MCRB Seres Therapeutics | $8.26
+1.3% | 3/20/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $25.00 -> $25.00 | Medium | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 3/20/2025 |
RGNX REGENXBIO | $9.81
+2.9% | 3/20/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $52.00 -> $52.00 | Low | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 3/20/2025 |
PRME Prime Medicine | $1.55
-7.2% | 3/20/2025 | Target Raised by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $15.00 -> $16.00 | High | View details for Chardan Capital rating of Prime Medicine (NYSE:PRME) on 3/20/2025 |
COYA Coya Therapeutics | $5.63
-4.3% | 3/20/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $14.00 -> $14.00 | Medium | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 3/20/2025 |
STOK Stoke Therapeutics | $11.36
+2.1% | 3/19/2025 | Reiterated by | Chardan Capital | Analyst R. Li | Buy -> Buy | $24.00 -> $24.00 | Low | View details for Chardan Capital rating of Stoke Therapeutics (NASDAQ:STOK) on 3/19/2025 |
The Robotics Revolution has arrived … and one $7 stock could take off as a result. (Ad) Something big is brewing in Washington.
According to my research, an executive order from President Trump could be just weeks away.
And it holds the potential to trigger one of the most explosive tech booms in US history.
At the center of it all? Robots.
Not the kind that clean your house or pour you coffee.
But the kind that could reshape entire industries, add $1.2 trillion per year to the US economy, and affect 65 million American lives — just in the next year. This little-known company holds nearly 100 patents and trades for around $7 |
RNA Avidity Biosciences | $33.62
+2.9% | 3/17/2025 | Reiterated by | Chardan Capital | Analyst K. Nakae | Buy -> Buy | $65.00 -> $65.00 | High | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 3/17/2025 |
DYN Dyne Therapeutics | $14.78
+2.6% | 3/17/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $50.00 -> $50.00 | Medium | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 3/17/2025 |
PRQR ProQR Therapeutics | $1.77
-3.3% | 3/14/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $4.00 -> $4.00 | High | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 3/14/2025 |
RGNX REGENXBIO | $9.81
+2.9% | 3/14/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $52.00 -> $52.00 | High | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 3/14/2025 |
OCS Oculis | $19.79
-0.7% | 3/13/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $28.00 -> $28.00 | Low | View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 3/13/2025 |
CRVO CervoMed | $7.72
-0.3% | 3/13/2025 | Upgraded by | Chardan Capital | Analyst D. Gataulin | Neutral -> Buy | $14.00 -> $14.00 | High | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 3/13/2025 |
TNYA Tenaya Therapeutics | $0.69
+0.7% | 3/12/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $18.00 -> $9.00 | High | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 3/12/2025 |
UBX Unity Biotechnology | $0.81
+16.0% | 3/10/2025 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $6.00 -> $6.00 | Low | View details for Chardan Capital rating of Unity Biotechnology (NASDAQ:UBX) on 3/10/2025 |
SLDB Solid Biosciences | $4.83
+4.5% | 3/7/2025 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $16.00 -> $16.00 | Low | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 3/7/2025 |
EYPT EyePoint Pharmaceuticals | $9.21
+3.1% | 3/6/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $33.00 -> $33.00 | High | View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 3/6/2025 |
OCGN Ocugen | $1.13
+3.7% | 3/6/2025 | Target Raised by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $6.00 -> $7.00 | High | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 3/6/2025 |
PASG Passage Bio | $0.48
+3.9% | 3/4/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $7.00 -> $6.00 | Medium | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 3/4/2025 |
FDMT 4D Molecular Therapeutics | $4.47
-6.7% | 3/4/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $30.00 -> $28.00 | High | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 3/4/2025 |
PRME Prime Medicine | $1.55
-7.2% | 3/3/2025 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $15.00 -> $15.00 | High | View details for Chardan Capital rating of Prime Medicine (NYSE:PRME) on 3/3/2025 |
IOVA Iovance Biotherapeutics | $2.38
+7.7% | 3/3/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $34.00 -> $30.00 | High | View details for Chardan Capital rating of Iovance Biotherapeutics (NASDAQ:IOVA) on 3/3/2025 |
NTLA Intellia Therapeutics | $8.47
+2.3% | 2/28/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $91.00 -> $68.00 | Medium | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 2/28/2025 |
RCKT Rocket Pharmaceuticals | $3.16
+4.6% | 2/28/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $62.00 -> $54.00 | Low | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 2/28/2025 |
DYN Dyne Therapeutics | $14.78
+2.6% | 2/28/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $50.00 -> $50.00 | High | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 2/28/2025 |
RNA Avidity Biosciences | $33.62
+2.9% | 2/28/2025 | Reiterated by | Chardan Capital | Analyst K. Nakae | Buy -> Buy | $65.00 -> $65.00 | High | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 2/28/2025 |
CGTX Cognition Therapeutics | $0.31
+3.9% | 2/26/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $11.00 -> $11.00 | Low | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 2/26/2025 |
TSHA Taysha Gene Therapies | $2.61
-6.8% | 2/26/2025 | Reiterated by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $7.00 -> $7.00 | Low | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 2/26/2025 |
ALNY Alnylam Pharmaceuticals | $302.46
-0.5% | 2/26/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $300.00 -> $300.00 | Low | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 2/26/2025 |
MGTX MeiraGTx | $6.86
+8.5% | 2/24/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $36.00 -> $36.00 | High | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 2/24/2025 |
PRTA Prothena | $5.26
+0.2% | 2/21/2025 | Reiterated by | Chardan Capital | Analyst R. Li | Buy -> Buy | $40.00 -> $40.00 | High | View details for Chardan Capital rating of Prothena (NASDAQ:PRTA) on 2/21/2025 |
KRYS Krystal Biotech | $138.21
+1.6% | 2/20/2025 | Target Raised by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $212.00 -> $218.00 | High | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 2/20/2025 |
SLDB Solid Biosciences | $4.83
+4.5% | 2/19/2025 | Target Raised by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $15.00 -> $16.00 | High | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 2/19/2025 |
STOK Stoke Therapeutics | $11.36
+2.1% | 2/19/2025 | Reiterated by | Chardan Capital | Analyst R. Li | Buy -> Buy | $24.00 -> $24.00 | High | View details for Chardan Capital rating of Stoke Therapeutics (NASDAQ:STOK) on 2/19/2025 |
OTLK Outlook Therapeutics | $1.84
-3.2% | 2/18/2025 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Neutral -> Neutral | $3.00 -> $3.00 | High | View details for Chardan Capital rating of Outlook Therapeutics (NASDAQ:OTLK) on 2/18/2025 |
OCGN Ocugen | $1.13
+3.7% | 2/13/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $6.00 -> $6.00 | High | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 2/13/2025 |
CRSP CRISPR Therapeutics | $42.94
+2.0% | 2/13/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $94.00 -> $84.00 | Low | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 2/13/2025 |
ARWR Arrowhead Pharmaceuticals | $16.97
+2.4% | 2/11/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $60.00 -> $60.00 | High | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 2/11/2025 |
FDMT 4D Molecular Therapeutics | $4.47
-6.7% | 2/11/2025 | Target Lowered by | Chardan Capital | Analyst Geulah Livshits | Buy -> Buy | $39.00 -> $30.00 | High | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 2/11/2025 |
COYA Coya Therapeutics | $5.63
-4.3% | 2/6/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $14.00 -> $14.00 | Medium | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 2/6/2025 |
EYPT EyePoint Pharmaceuticals | $9.21
+3.1% | 2/6/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $33.00 -> $33.00 | High | View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 2/6/2025 |
CRGX CARGO Therapeutics | $4.59
-1.1% | 1/30/2025 | Downgraded by | Chardan Capital | Analyst Geulah Livshits | Buy -> Neutral | | N/A | View details for Chardan Capital rating of CARGO Therapeutics (NASDAQ:CRGX) on 1/30/2025 |
SABS SAB Biotherapeutics | $1.87
+0.5% | 1/29/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $25.00 -> $25.00 | Medium | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 1/29/2025 |
OCGN Ocugen | $1.13
+3.7% | 1/23/2025 | Reiterated by | Chardan Capital | Analyst Daniil Gataulin | Buy -> Buy | $6.00 -> $6.00 | High | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 1/23/2025 |
DYN Dyne Therapeutics | $14.78
+2.6% | 1/10/2025 | Reiterated by | Chardan Capital | Analyst Keay Nakae | Buy -> Buy | $50.00 -> $50.00 | High | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 1/10/2025 |
UBX Unity Biotechnology | $0.81
+16.0% | 1/10/2025 | Initiated by | Chardan Capital | Analyst D. Gataulin | Buy | $6.00 | High | View details for Chardan Capital rating of Unity Biotechnology (NASDAQ:UBX) on 1/10/2025 |
IMRX Immuneering | $2.17
| 1/8/2025 | Reiterated by | Chardan Capital | - | Buy -> Buy | $13.00 -> $13.00 | Medium | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 1/8/2025 |
OCS Oculis | $19.79
-0.7% | 1/7/2025 | Reiterated by | Chardan Capital | - | Buy -> Buy | $28.00 -> $28.00 | High | View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 1/7/2025 |
STOK Stoke Therapeutics | $11.36
+2.1% | 12/20/2024 | Initiated by | Chardan Capital | Analyst R. Li | Buy | $24.00 | N/A | View details for Chardan Capital rating of Stoke Therapeutics (NASDAQ:STOK) on 12/20/2024 |
PRTA Prothena | $5.26
+0.2% | 12/20/2024 | Initiated by | Chardan Capital | Analyst R. Li | Buy | $40.00 | N/A | View details for Chardan Capital rating of Prothena (NASDAQ:PRTA) on 12/20/2024 |
MNMD Mind Medicine (MindMed) | $7.89
+1.7% | 12/20/2024 | Initiated by | Chardan Capital | Analyst R. Li | Buy | $20.00 | N/A | View details for Chardan Capital rating of Mind Medicine (MindMed) (NASDAQ:MNMD) on 12/20/2024 |
CGTX Cognition Therapeutics | $0.31
+3.9% | 12/19/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $11.00 -> $11.00 | N/A | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 12/19/2024 |
KRYS Krystal Biotech | $138.21
+1.6% | 12/18/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $212.00 -> $212.00 | N/A | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 12/18/2024 |
TNYA Tenaya Therapeutics | $0.69
+0.7% | 12/18/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $18.00 -> $18.00 | N/A | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 12/18/2024 |
INOD Innodata | $43.27
-11.1% | 12/13/2024 | Reiterated by | Chardan Capital | - | Buy | $45.00 | N/A | View details for Chardan Capital rating of Innodata (NASDAQ:INOD) on 12/13/2024 |
EDIT Editas Medicine | $2.10
+8.8% | 12/13/2024 | Reiterated by | Chardan Capital | Analyst Y. Livshits | Buy -> Neutral | | N/A | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 12/13/2024 |
KRYS Krystal Biotech | $138.21
+1.6% | 12/12/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $212.00 -> $212.00 | N/A | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 12/12/2024 |
Trump’s Exec Order #14154 could be a “Millionaire-Maker” (Ad) Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.”
We recently sat down with Rickards to capture all the key details on tape.
 For the moment, you can watch this interview free of charge – just click here. |
ARWR Arrowhead Pharmaceuticals | $16.97
+2.4% | 12/12/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $60.00 -> $60.00 | N/A | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 12/12/2024 |
PRQR ProQR Therapeutics | $1.77
-3.3% | 12/12/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $4.00 -> $4.00 | N/A | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 12/12/2024 |
CRVO CervoMed | $7.72
-0.3% | 12/11/2024 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Neutral | | N/A | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 12/11/2024 |
SLN Silence Therapeutics | $5.15
-3.0% | 12/10/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $55.00 -> $55.00 | N/A | View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 12/10/2024 |
CRSP CRISPR Therapeutics | $42.94
+2.0% | 12/10/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $94.00 -> $94.00 | N/A | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 12/10/2024 |
FBRX Forte Biosciences | $12.25
+2.5% | 12/4/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $64.00 -> $64.00 | N/A | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 12/4/2024 |
SNTI Senti Biosciences | $3.02
-3.2% | 12/2/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $10.00 -> $10.00 | N/A | View details for Chardan Capital rating of Senti Biosciences (NASDAQ:SNTI) on 12/2/2024 |
OTLK Outlook Therapeutics | $1.84
-3.2% | 12/2/2024 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Neutral | | N/A | View details for Chardan Capital rating of Outlook Therapeutics (NASDAQ:OTLK) on 12/2/2024 |
ARWR Arrowhead Pharmaceuticals | $16.97
+2.4% | 11/27/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $60.00 -> $60.00 | N/A | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 11/27/2024 |
MGX Metagenomi | $1.57
-6.0% | 11/20/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $15.00 -> $15.00 | N/A | View details for Chardan Capital rating of Metagenomi (NASDAQ:MGX) on 11/20/2024 |
IMRX Immuneering | $2.17
| 11/20/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $13.00 -> $13.00 | N/A | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 11/20/2024 |
RGNX REGENXBIO | $9.81
+2.9% | 11/20/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $52.00 -> $52.00 | N/A | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 11/20/2024 |
ABUS Arbutus Biopharma | $3.55
+1.1% | 11/20/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $4.50 -> $5.00 | N/A | View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 11/20/2024 |
RCKT Rocket Pharmaceuticals | $3.16
+4.6% | 11/18/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $62.00 -> $62.00 | N/A | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 11/18/2024 |
OCGN Ocugen | $1.13
+3.7% | 11/18/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $6.00 -> $6.00 | N/A | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 11/18/2024 |
MGTX MeiraGTx | $6.86
+8.5% | 11/18/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $36.00 -> $36.00 | N/A | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 11/18/2024 |
NTLA Intellia Therapeutics | $8.47
+2.3% | 11/18/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $88.00 -> $91.00 | N/A | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 11/18/2024 |
FBRX Forte Biosciences | $12.25
+2.5% | 11/15/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $3.00 -> $64.00 | N/A | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 11/15/2024 |
CGTX Cognition Therapeutics | $0.31
+3.9% | 11/15/2024 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $11.00 -> $11.00 | N/A | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 11/15/2024 |
CLSD Clearside Biomedical | $0.81
+6.4% | 11/15/2024 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $6.00 -> $6.00 | N/A | View details for Chardan Capital rating of Clearside Biomedical (NASDAQ:CLSD) on 11/15/2024 |
CRVO CervoMed | $7.72
-0.3% | 11/14/2024 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $55.00 -> $55.00 | N/A | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 11/14/2024 |
TSHA Taysha Gene Therapies | $2.61
-6.8% | 11/14/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $7.00 -> $7.00 | N/A | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 11/14/2024 |
PASG Passage Bio | $0.48
+3.9% | 11/14/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $7.00 -> $7.00 | N/A | View details for Chardan Capital rating of Passage Bio (NASDAQ:PASG) on 11/14/2024 |
FDMT 4D Molecular Therapeutics | $4.47
-6.7% | 11/14/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $39.00 -> $39.00 | N/A | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 11/14/2024 |
SLN Silence Therapeutics | $5.15
-3.0% | 11/14/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $55.00 -> $55.00 | N/A | View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 11/14/2024 |
ALUR Allurion Technologies | $2.73
+0.7% | 11/14/2024 | Downgraded by | Chardan Capital | Analyst K. Nakae | Buy -> Neutral | | N/A | View details for Chardan Capital rating of Allurion Technologies (NYSE:ALUR) on 11/14/2024 |
MCRB Seres Therapeutics | $8.26
+1.3% | 11/13/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $25.00 -> $25.00 | N/A | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 11/13/2024 |
RNA Avidity Biosciences | $33.62
+2.9% | 11/13/2024 | Reiterated by | Chardan Capital | Analyst K. Nakae | Buy -> Buy | $65.00 -> $65.00 | N/A | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 11/13/2024 |
DYN Dyne Therapeutics | $14.78
+2.6% | 11/13/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $50.00 -> $50.00 | N/A | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 11/13/2024 |
OBIO Orchestra BioMed | $3.34
| 11/13/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $20.00 -> $20.00 | N/A | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 11/13/2024 |
PRME Prime Medicine | $1.55
-7.2% | 11/13/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $17.00 -> $15.00 | N/A | View details for Chardan Capital rating of Prime Medicine (NYSE:PRME) on 11/13/2024 |
FEMY Femasys | $0.80
0.0% | 11/13/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $10.00 -> $8.00 | N/A | View details for Chardan Capital rating of Femasys (NASDAQ:FEMY) on 11/13/2024 |
CRGX CARGO Therapeutics | $4.59
-1.1% | 11/13/2024 | Reiterated by | Chardan Capital | Analyst G. Livshits | Buy -> Buy | $28.00 -> $28.00 | N/A | View details for Chardan Capital rating of CARGO Therapeutics (NASDAQ:CRGX) on 11/13/2024 |
LXEO Lexeo Therapeutics | $4.61
+5.3% | 11/13/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $23.00 -> $25.00 | N/A | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 11/13/2024 |
SLDB Solid Biosciences | $4.83
+4.5% | 11/11/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $15.00 -> $15.00 | N/A | View details for Chardan Capital rating of Solid Biosciences (NASDAQ:SLDB) on 11/11/2024 |
RCKT Rocket Pharmaceuticals | $3.16
+4.6% | 11/11/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $62.00 -> $62.00 | N/A | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 11/11/2024 |
ZURA Zura Bio | $1.28
+2.4% | 11/8/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $14.00 -> $12.00 | N/A | View details for Chardan Capital rating of Zura Bio (NASDAQ:ZURA) on 11/8/2024 |
OCGN Ocugen | $1.13
+3.7% | 11/8/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $6.00 -> $6.00 | N/A | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 11/8/2024 |
EYPT EyePoint Pharmaceuticals | $9.21
+3.1% | 11/8/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $28.00 -> $33.00 | N/A | View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 11/8/2024 |
SABS SAB Biotherapeutics | $1.87
+0.5% | 11/7/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $25.00 -> $25.00 | N/A | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 11/7/2024 |
TNYA Tenaya Therapeutics | $0.69
+0.7% | 11/7/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $20.00 -> $18.00 | N/A | View details for Chardan Capital rating of Tenaya Therapeutics (NASDAQ:TNYA) on 11/7/2024 |
COYA Coya Therapeutics | $5.63
-4.3% | 11/7/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $14.00 -> $14.00 | N/A | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 11/7/2024 |
IPSC Century Therapeutics | $0.63
+1.3% | 11/7/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $17.00 -> $11.00 | N/A | View details for Chardan Capital rating of Century Therapeutics (NASDAQ:IPSC) on 11/7/2024 |
ABUS Arbutus Biopharma | $3.55
+1.1% | 11/6/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $4.00 -> $4.50 | N/A | View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 11/6/2024 |
EDIT Editas Medicine | $2.10
+8.8% | 11/5/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $12.00 -> $12.00 | Low | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 11/5/2024 |
ALNY Alnylam Pharmaceuticals | $302.46
-0.5% | 11/1/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $300.00 -> $300.00 | High | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 11/1/2024 |
CGTX Cognition Therapeutics | $0.31
+3.9% | 10/31/2024 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $11.00 -> $11.00 | Low | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 10/31/2024 |
COYA Coya Therapeutics | $5.63
-4.3% | 10/30/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $14.00 -> $14.00 | High | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 10/30/2024 |
RNA Avidity Biosciences | $33.62
+2.9% | 10/30/2024 | Target Raised by | Chardan Capital | Analyst K. Nakae | Buy -> Buy | $60.00 -> $65.00 | High | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 10/30/2024 |
EYPT EyePoint Pharmaceuticals | $9.21
+3.1% | 10/29/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $28.00 -> $28.00 | Low | View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 10/29/2024 |
Trump’s Exec Order #14154 could be a “Millionaire-Maker” (Ad) Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.”
We recently sat down with Rickards to capture all the key details on tape.
For the moment, you can watch this interview free of charge – just click here. |
LXEO Lexeo Therapeutics | $4.61
+5.3% | 10/25/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $23.00 -> $23.00 | Low | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 10/25/2024 |
NTLA Intellia Therapeutics | $8.47
+2.3% | 10/24/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $94.00 -> $88.00 | Low | View details for Chardan Capital rating of Intellia Therapeutics (NASDAQ:NTLA) on 10/24/2024 |
EDIT Editas Medicine | $2.10
+8.8% | 10/22/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $20.00 -> $12.00 | Medium | View details for Chardan Capital rating of Editas Medicine (NASDAQ:EDIT) on 10/22/2024 |
RGNX REGENXBIO | $9.81
+2.9% | 10/22/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $52.00 -> $52.00 | High | View details for Chardan Capital rating of REGENXBIO (NASDAQ:RGNX) on 10/22/2024 |
CLSD Clearside Biomedical | $0.81
+6.4% | 10/14/2024 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $6.00 -> $6.00 | Low | View details for Chardan Capital rating of Clearside Biomedical (NASDAQ:CLSD) on 10/14/2024 |
ALNY Alnylam Pharmaceuticals | $302.46
-0.5% | 10/11/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $300.00 -> $300.00 | Low | View details for Chardan Capital rating of Alnylam Pharmaceuticals (NASDAQ:ALNY) on 10/11/2024 |
FDMT 4D Molecular Therapeutics | $4.47
-6.7% | 9/19/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $38.00 -> $39.00 | High | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 9/19/2024 |
CRVO CervoMed | $7.72
-0.3% | 9/18/2024 | Initiated by | Chardan Capital | Analyst D. Gataulin | Buy | $55.00 | Medium | View details for Chardan Capital rating of CervoMed (NASDAQ:CRVO) on 9/18/2024 |
SABS SAB Biotherapeutics | $1.87
+0.5% | 9/9/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $25.00 -> $25.00 | Medium | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 9/9/2024 |
MGX Metagenomi | $1.57
-6.0% | 9/5/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $15.00 -> $15.00 | Low | View details for Chardan Capital rating of Metagenomi (NASDAQ:MGX) on 9/5/2024 |
ALUR Allurion Technologies | $2.73
+0.7% | 8/22/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $125.00 -> $62.50 | Low | View details for Chardan Capital rating of Allurion Technologies (NYSE:ALUR) on 8/22/2024 |
CLSD Clearside Biomedical | $0.81
+6.4% | 8/21/2024 | Initiated by | Chardan Capital | Analyst D. Gataulin | Buy | $6.00 | Low | View details for Chardan Capital rating of Clearside Biomedical (NASDAQ:CLSD) on 8/21/2024 |
FBRX Forte Biosciences | $12.25
+2.5% | 8/19/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $3.00 -> $3.00 | Low | View details for Chardan Capital rating of Forte Biosciences (NASDAQ:FBRX) on 8/19/2024 |
MGX Metagenomi | $1.57
-6.0% | 8/19/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $17.00 -> $15.00 | Low | View details for Chardan Capital rating of Metagenomi (NASDAQ:MGX) on 8/19/2024 |
OTLK Outlook Therapeutics | $1.84
-3.2% | 8/16/2024 | Reiterated by | Chardan Capital | Analyst D. Gataulin | Buy -> Buy | $53.00 -> $53.00 | Low | View details for Chardan Capital rating of Outlook Therapeutics (NASDAQ:OTLK) on 8/16/2024 |
SLN Silence Therapeutics | $5.15
-3.0% | 8/16/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $55.00 -> $55.00 | Low | View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 8/16/2024 |
FEMY Femasys | $0.80
0.0% | 8/14/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $12.00 -> $10.00 | Low | View details for Chardan Capital rating of Femasys (NASDAQ:FEMY) on 8/14/2024 |
LXEO Lexeo Therapeutics | $4.61
+5.3% | 8/14/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $23.00 -> $23.00 | Low | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 8/14/2024 |
MCRB Seres Therapeutics | $8.26
+1.3% | 8/14/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $25.00 -> $25.00 | Low | View details for Chardan Capital rating of Seres Therapeutics (NASDAQ:MCRB) on 8/14/2024 |
TSHA Taysha Gene Therapies | $2.61
-6.8% | 8/13/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $7.00 -> $7.00 | Low | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 8/13/2024 |
SABS SAB Biotherapeutics | $1.87
+0.5% | 8/12/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $25.00 -> $25.00 | Low | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 8/12/2024 |
GANX Gain Therapeutics | $1.89
-1.0% | 8/9/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $6.00 -> $6.00 | Low | View details for Chardan Capital rating of Gain Therapeutics (NASDAQ:GANX) on 8/9/2024 |
RNA Avidity Biosciences | $33.62
+2.9% | 8/9/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $45.00 -> $60.00 | Low | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 8/9/2024 |
IMRX Immuneering | $2.17
| 8/7/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $16.00 -> $12.00 | Low | View details for Chardan Capital rating of Immuneering (NASDAQ:IMRX) on 8/7/2024 |
CRSP CRISPR Therapeutics | $42.94
+2.0% | 8/6/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $112.00 -> $94.00 | Low | View details for Chardan Capital rating of CRISPR Therapeutics (NASDAQ:CRSP) on 8/6/2024 |
RCKT Rocket Pharmaceuticals | $3.16
+4.6% | 8/6/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $62.00 -> $62.00 | Low | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 8/6/2024 |
KRYS Krystal Biotech | $138.21
+1.6% | 8/5/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $153.00 -> $208.00 | Low | View details for Chardan Capital rating of Krystal Biotech (NASDAQ:KRYS) on 8/5/2024 |
PHMMF Pharma Mar | $104.49
+0.9% | 8/1/2024 | Upgraded by | Chardan Capital | Analyst K. Nakae | Strong-Buy | | Low | View details for Chardan Capital rating of Pharma Mar (OTCMKTS:PHMMF) on 8/1/2024 |
MGTX MeiraGTx | $6.86
+8.5% | 7/31/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $36.00 | Low | View details for Chardan Capital rating of MeiraGTx (NASDAQ:MGTX) on 7/31/2024 |
ADVM Adverum Biotechnologies | $2.79
-6.1% | 7/18/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $4.00 -> $40.00 | Low | View details for Chardan Capital rating of Adverum Biotechnologies (NASDAQ:ADVM) on 7/18/2024 |
ARWR Arrowhead Pharmaceuticals | $16.97
+2.4% | 7/17/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $60.00 -> $60.00 | Low | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 7/17/2024 |
FDMT 4D Molecular Therapeutics | $4.47
-6.7% | 7/17/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $38.00 -> $38.00 | Low | View details for Chardan Capital rating of 4D Molecular Therapeutics (NASDAQ:FDMT) on 7/17/2024 |
LXEO Lexeo Therapeutics | $4.61
+5.3% | 7/15/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $23.00 -> $23.00 | Low | View details for Chardan Capital rating of Lexeo Therapeutics (NASDAQ:LXEO) on 7/15/2024 |
CRGX CARGO Therapeutics | $4.59
-1.1% | 7/8/2024 | Initiated by | Chardan Capital | Analyst G. Livshits | Buy | $28.00 | Low | View details for Chardan Capital rating of CARGO Therapeutics (NASDAQ:CRGX) on 7/8/2024 |
RCKT Rocket Pharmaceuticals | $3.16
+4.6% | 6/28/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $62.00 -> $62.00 | Low | View details for Chardan Capital rating of Rocket Pharmaceuticals (NASDAQ:RCKT) on 6/28/2024 |
SLN Silence Therapeutics | $5.15
-3.0% | 6/28/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $42.00 -> $55.00 | Low | View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 6/28/2024 |
EYPT EyePoint Pharmaceuticals | $9.21
+3.1% | 6/28/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $28.00 -> $28.00 | Low | View details for Chardan Capital rating of EyePoint Pharmaceuticals (NASDAQ:EYPT) on 6/28/2024 |
ARWR Arrowhead Pharmaceuticals | $16.97
+2.4% | 6/26/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $60.00 -> $60.00 | Low | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 6/26/2024 |
TSHA Taysha Gene Therapies | $2.61
-6.8% | 6/18/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $7.00 -> $7.00 | Low | View details for Chardan Capital rating of Taysha Gene Therapies (NASDAQ:TSHA) on 6/18/2024 |
RNA Avidity Biosciences | $33.62
+2.9% | 6/12/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $33.00 -> $45.00 | Low | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 6/12/2024 |
OBIO Orchestra BioMed | $3.34
| 6/12/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $20.00 -> $20.00 | Low | View details for Chardan Capital rating of Orchestra BioMed (NASDAQ:OBIO) on 6/12/2024 |
OCS Oculis | $19.79
-0.7% | 6/11/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $30.00 -> $30.00 | Low | View details for Chardan Capital rating of Oculis (NASDAQ:OCS) on 6/11/2024 |
CGTX Cognition Therapeutics | $0.31
+3.9% | 6/6/2024 | Initiated by | Chardan Capital | Analyst D. Gataulin | Buy | $11.00 | Low | View details for Chardan Capital rating of Cognition Therapeutics (NASDAQ:CGTX) on 6/6/2024 |
COYA Coya Therapeutics | $5.63
-4.3% | 6/5/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $14.00 -> $14.00 | Low | View details for Chardan Capital rating of Coya Therapeutics (NASDAQ:COYA) on 6/5/2024 |
ABUS Arbutus Biopharma | $3.55
+1.1% | 6/5/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $4.00 -> $4.00 | Low | View details for Chardan Capital rating of Arbutus Biopharma (NASDAQ:ABUS) on 6/5/2024 |
IBIO iBio | $0.95
+3.9% | 6/3/2024 | Reiterated by | Chardan Capital | Analyst K. Nakae | Buy -> Buy | $5.00 -> $5.00 | Low | View details for Chardan Capital rating of iBio (NYSE:IBIO) on 6/3/2024 |
ARWR Arrowhead Pharmaceuticals | $16.97
+2.4% | 6/3/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $60.00 -> $60.00 | Low | View details for Chardan Capital rating of Arrowhead Pharmaceuticals (NASDAQ:ARWR) on 6/3/2024 |
NVX NOVONIX | $1.21
+5.2% | 5/30/2024 | Initiated by | Chardan Capital | Analyst B. Dobson | Buy | $4.00 | Low | View details for Chardan Capital rating of NOVONIX (NASDAQ:NVX) on 5/30/2024 |
IBIO iBio | $0.95
+3.9% | 5/28/2024 | Initiated by | Chardan Capital | Analyst K. Nakae | Buy | $5.00 | Low | View details for Chardan Capital rating of iBio (NYSE:IBIO) on 5/28/2024 |
CRGO Freightos | $2.32
+0.9% | 5/23/2024 | Target Lowered by | Chardan Capital | - | Buy -> Buy | $8.00 -> $6.00 | Low | View details for Chardan Capital rating of Freightos (NASDAQ:CRGO) on 5/23/2024 |
SABS SAB Biotherapeutics | $1.87
+0.5% | 5/21/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $25.00 -> $25.00 | Low | View details for Chardan Capital rating of SAB Biotherapeutics (NASDAQ:SABS) on 5/21/2024 |
DYN Dyne Therapeutics | $14.78
+2.6% | 5/21/2024 | Target Raised by | Chardan Capital | - | Buy -> Buy | $31.00 -> $42.00 | Low | View details for Chardan Capital rating of Dyne Therapeutics (NASDAQ:DYN) on 5/21/2024 |
BMTX BM Technologies | $5.00
| 5/20/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $8.00 -> $8.00 | Low | View details for Chardan Capital rating of BM Technologies (NYSE:BMTX) on 5/20/2024 |
SLN Silence Therapeutics | $5.15
-3.0% | 5/17/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $42.00 -> $42.00 | Low | View details for Chardan Capital rating of Silence Therapeutics (NASDAQ:SLN) on 5/17/2024 |
ALUR Allurion Technologies | $2.73
+0.7% | 5/15/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $125.00 -> $125.00 | Low | View details for Chardan Capital rating of Allurion Technologies (NYSE:ALUR) on 5/15/2024 |
OCGN Ocugen | $1.13
+3.7% | 5/15/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $5.00 -> $5.00 | Low | View details for Chardan Capital rating of Ocugen (NASDAQ:OCGN) on 5/15/2024 |
VFS VinFast Auto | $3.51
-1.7% | 5/13/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $13.00 -> $13.00 | Low | View details for Chardan Capital rating of VinFast Auto (NASDAQ:VFS) on 5/13/2024 |
CLSK CleanSpark | $10.13
+0.1% | 5/13/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $26.00 -> $26.00 | Low | View details for Chardan Capital rating of CleanSpark (NASDAQ:CLSK) on 5/13/2024 |
RNA Avidity Biosciences | $33.62
+2.9% | 5/10/2024 | Reiterated by | Chardan Capital | - | Buy -> Buy | $33.00 -> $33.00 | Low | View details for Chardan Capital rating of Avidity Biosciences (NASDAQ:RNA) on 5/10/2024 |
PRQR ProQR Therapeutics | $1.77
-3.3% | 5/10/2024 | Reiterated by | Chardan Capital | Analyst K. Nakae | Buy -> Buy | $2.50 -> $2.50 | Low | View details for Chardan Capital rating of ProQR Therapeutics (NASDAQ:PRQR) on 5/10/2024 |
